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Mitral regurgitation is the valvular heart disease with the
highest prevalence in the Western countries, and its
prevalence increases with age.1 Conventional surgery
provides excellent results in the younger population free
of comorbidities, but up to 50% of the patients with
severe mitral regurgitation are today denied surgery
because of increased surgical risk.2 During the last few
years, transcatheter valve interventions have emerged as
a therapeutic option to treat inoperable or high-risk
patients who are not amenable for conventional open-
heart surgery.3
Several surgical procedures have inspired transcatheter
devices to treat mitral regurgitation, ranging from leaflet
repair, annular and ventricular remodelling and valve
replacement. Today, transcatheter edge-to-edge repair
with the MitraClip system (Abbott Vascular Inc., Menlo
Park, California, USA) is the most advanced technology
available for clinical use, with proven safety, efficacy and
durability in different clinical settings.3 In addition to the
MitraClip system, different technologies with diversified
approaches are today under development to improve the
transcatheter mitral valve repair (TMVR) armamentar-
ium.4 Transcatheter mitral valve implantation (TMVI)
has recently became an option for those patients with
previous open-heart surgery and a degenerated bio-
prosthesis or with recurrent mitral regurgitation following
annuloplasty.5 Although transcatheter mitral implant in a
native anatomy introduces a number of challenges, the
feasibility of TMVI in human has been recently reported
in high-risk patients with functional and degenerative
aetiology. Five devices have been tested in clinical
studies with variable outcomes (Fig. 1).
As replacement technologies are developed, it should be
questioned whether TMVI should become the preferred
transcatheter mitral valve therapy. TMVI promises
several advantages. It has the potential to be more
reproducible, applicable to many patients (one valve
for all), associated with predictable results and to be less
technically demanding and easier to learn procedure. On
the other hand, TMVR, although more technically chal-
lenging, may be associated with a superior safety profile,
as compared with replacement, as it involves a less acute
change in valve anatomy and physiology, does not involve
a tissue implant and does not require anticoagulation.
As the future interventions are developing, it is difficult
to predict which technology will prevail; however, it is not
difficult to predict that there will be a role for both
procedures, such as the case with surgery.
Previous clinical experiences from surgery
Although transcatheter interventions may act differently,
surgical background can be the source of inspiration for
the future.
In the early days of cardiac surgery, before heart–lung
machine technology was established, several off-pump
mitral repair techniques were attempted, mainly directed
at annular remodelling. With the introduction of the
open-heart approach and the development of artificial
prostheses, repair disappeared progressively from the
surgical arena. Surgeons preferred replacement because
it is easier to perform and more predictable because of
the more reproducible approach provided by valve repla-
cement. However, in the late 1980s and early 1990s,
mitral repair gained progressively more acceptance and
became the gold standard treatment of mitral regurgita-
tion due to a higher safety profile, both in terms of
hospital mortality and long-term comorbidity and quality
of life. The main limitation of mitral valve replacement
is that the ideal replacement prosthesis should have the
following characteristics: durability, easy and reproduci-
ble implant, absence of transvalvular gradient, absence of
valve regurgitation, no risk of Left Ventricle Outflow
Tract (LVOT) obstruction, no need for anticoagulation,
no deterioration of left ventricular (LV) function, respect
of LV physiology and blood flow pattern. In short, the
ideal prosthesis does not exist.
Until the late 1990s, mitral repair was performed only
by selected ‘dedicated’ physicians, who developed
specific skills and expertise to deliver reliable outcomes
in a variety of clinical and anatomical scenarios. Only
recently, after more than 2 decades of surgical practice
and strong educational efforts, mitral repair is performed
by almost all high-volume cardiac surgeons, with
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standardized approach and reproducible outcomes. Valve
replacement still plays a role, but as a second-line option,
when repair efficacy and durability are questionable.
The current scenario may repeat now and in the near
future in the field of transcatheter valve interventions:
repair and replacement will be confronted with their
strengths and limitations, and will very probably find a
complementary role.
Surgical literature has shown that in patients with degen-
erative mitral regurgitation (DMR), valve repair, as com-
pared with replacement, yields superior acute and long-
terms outcomes, both in terms ofmorbidity andmortality.
Therefore, surgical mitral valve repair is the treatment of
choice for patients with severe DMR, owing to its well
documented advantages over mitral valve replacement in
terms of morbidity and mortality.6
Effective and timely correction of DMR has a highly
beneficial impact on the prognosis of patients and can
even be associated with a life expectancy and a quality of
life similar to those of the age-matched general popu-
lation.7 The positive prognostic benefit of early interven-
tion in young patients with DMR is lost when a prosthesis
is implanted, due to the prosthesis-related morbidity and
mortality. Therefore, life expectancy of a patient with a
prosthetic valve is reduced,mainly due to thromboembolic
and haemorrhagic events and to the risk of prosthetic-
related endocarditis.8 Thromboembolic complications are
the most important cause of morbidity and mortality in
patients with a prosthetic heart valve, with an estimated
incidence of clinical events ranging from 0.6 to 2.3% per
patient-year.9 The risk of thromboembolic complications
is similar for patients with mechanical valves on warfarin
therapy and bioprosthetic valves without warfarin therapy.
Moreover, obstruction of a prosthetic valve may be caused
by thrombus formation, pannus ingrowth or their combi-
nation. The incidence of obstructive valve thrombosis
varies between 0.3 and 1.3% per patient-year in patients
with mechanical valves.9 Haemorrhagic complications are
another major concern related to long-term anticoagula-
tion, with an annual risk of 1% per patient-year.9,10 The
incidence of prosthetic valve endocarditis is around 0.5%
per patient-year, even with appropriate antibiotic prophy-
laxis. Prosthetic valve endocarditis is an extremely serious
condition with high mortality rates (30–50%).11
Superiority of mitral repair in the context of DMR has
been demonstrated also in elderly patients.12 In patients
with high surgical risk, benefits of repair are even more
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pronounced. TMVR cannot be applicable to all patients
due to intrinsic anatomical limitations (e.g. calcified
leaflets, advanced multisegment disease and large lesions
requiring resections), but anatomical variability can
also become a limitation for TMVI. As an example, most
current technologies rely on native leaflet and subvalvular
apparatus for fixation. Patients with advanced degenera-
tive anatomical lesions may be suboptimal candidates for
some replacement technologies.
Currently, the majority of the patients who undergo
transcatheter mitral interventions are high-risk patients
with functional mitral regurgitation (FMR). The benefits
of surgical repair over replacement in patients with FMR
are less clear compared with DMR patients.
Acker et al.13 in a large multicentre randomized trial
compared mitral repair (undersized annuloplasty) and
mitral replacement in 251 patients with severe ischaemic
FMR. The authors did not observe any significant differ-
ence in LV reverse remodelling or survival at 12 months
between patients who underwent mitral repair and
those who underwent mitral replacement, apart from a
higher recurrence in mitral regurgitation that was
observed in the repair group. The conclusion was that
replacement provided a more durable correction of mitral
regurgitation, although this was not associated with any
clinical impact. Although the study was not powered for
mortality, the repair patients showed a trend to better
early survival (30-day mortality almost three-fold higher
in the replacement group 4% compared with repair group
1.5%). Indeed, although significant recurrent mitral
regurgitation developed in more than 30% of the patients
in the repair group, the patients in this group who did
not have recurrent ischaemic mitral regurgitation realized
a 22.6% reduction in LV volume versus a 6.8% reduction
in the replacement group.
However, repair is not always effective, and patient
selection is extremely important to prevent the recur-
rence of FMR. Anatomical predictors of repair failure
should be taken into consideration when selecting
patients for restrictive annuloplasty to obtain a durable
repair.14
The current study suggests that particularly when treat-
ing FMR, repair can be beneficial even at the cost of a
higher recurrence rate due to a superior safety profile.
Safety will certainly play a central role in the future to
further expand mitral interventions into the lower risk
categories and to enable early treatment.
Mitral repair is also more suitable for an early indication
approach to overcome the prosthesis-related compli-
cations. In addition, when repair is applied early in the
course of the disease, the chance of effective mitral
regurgitation reduction is higher. These data support
the fact that if durable and effective mitral repair is
performed, also in the context of FMR a transcatheter
repair approach could be beneficial compared with
TMVI. TMVI should be preferred only in patients with
low likelihood of durable repair.
The reasons for the superiority of repair compared with
replacement in surgical experience finds a potential
ground in mitral valve anatomy and physiology.
Mitral valve complex and physiology
We are used to refer to the mitral as a ‘valve’. However,
the mitral is not only a simple valve: the mitral
is a ‘complex’ and should be considered as an integrated
part of the LV. The mitral valve complex is composed
by the leaflets, the annulus, the chordae, the papillary
muscles, it is in continuity with the atrial wall and
the aortic valve and plays a fundamental role in the
demarcation of the inflow–outflow ventricular tracts.
In addition to the simple function of valve, ensuring
unidirectional blood flow from left atrium to LV, the
mitral complex has structural and haemodynamic
functions too. Residual abnormalities of the heart struc-
tures after mitral replacement may compromise these
functions. At least some of these abnormalities are related
to the inherent properties of the valve substitute and
might conceivably be avoided or minimized by a more
physiological restoration, which is the aim of the mitral
valve repair.
The mitral valve apparatus and the LV are integrated
structures, connected by the chordae tendineae. The
proximity, structural continuity, design characteristics
and haemodynamic factors play an important role in
providing essential ‘crosstalk’ to achieve optimal function
of the mitral valve. Discontinuation of the structural
contiguity of mitral apparatus and LV after mitral valve
replacement results in LV maladaptive remodelling
and worse performance. Moreover, mitral annulus is a
three-dimensional dynamic structure, and its contraction
plays an important role in the determination of the
contractile function of the LV: the fixation of a prosthetic
valve to the mitral annulus makes it a static structure
and may lead to the reduction of the systolic contribution
of the basal portion of the LV to the ejection. This may be
an issue mainly in heart failure patients with reduced
Ejection Fraction (EF).
In addition to the structural function, the mitral complex
also plays an important haemodynamic role to direction
the blood flow. As described by Yacoub and Cohn,15 the
flow through the heart chambers is an integrated system
that depends on a combination of patterns of flow in and
out of the valves and implies a fluid–structure inter-
action. Imaging studies showed that in the LV inflow
through the open mitral valve gives rise to recirculating
flows beneath the valve leaflets, the dominant direction
being under the free edge of the anterior mitral leaflet.
Part of the blood volume is thus redirected towards
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the outflow tract, according to a vortex-like pattern.
Transient recirculation is also seen beneath the posterior
mitral valve leaflet.16,17
There is no doubt that such a complex interaction may be
preserved only with a reparative approach, aimed to
respect not only the anatomy, but also the physiology
of the mitral complex. Circulation is based on ‘dynamism
and crosstalk’, actions and reactions play a game the
principle of which is the preservation of energy. Loss
of the vortex-like circulation patterns means loss of
energy, which might result in increased LV stress and
less-efficient work.16
Access considerations
Although for TMVR, including edge-to-edge repair and
direct annuloplasty, the transeptal access is widely used,
access for TMVI still represents an issue. At the moment,
TMVI requires a large and rigid sheat, and this aspect
may affect the deliverability of the system, especially in
case of long route. Deliverability, in fact, depends on the
size of the delivery system, length of the device, rigidity,
time to deploy and patient’s haemodynamic at the
moment of the deployment (including need and duration
of rapid pacing).
At the moment, a transfemoral or transeptal approach
may be challenging in TMVI because of the angulation
and the deliverability of a large and rigid device across
the septum.
Direct transatrial approach is a possible alternative, which
has been used for mitral valve-in-ring procedures.18
However, direct transatrial approach has been almost
abandoned because of the lack of coaxiality of this access
within the mitral annulus.
Transapical approach represents so far the best route
for TMVI, assuring by definition of optimal coaxiality.
However, it should be considered that the LV wall in
heart failure patients with mitral regurgitation is totally
different from the LV wall of patients with aortic stenosis
and hypertrophy. In mitral regurgitation patients, LV
is usually thin, dilated, dysfunctional and arrhythmo-
genic. Therefore, apical access may represent an issue
in patients undergoing TMVI, potentially causing acute
LV dysfunction, EF worsening and haemodynamic
problems. Moreover, extremely compromised patients
with severely depressed EF may not tolerate transient
hypotension during rapid pacing. Last but not least, a
percutaneous approach is associated with faster recovery
and less ‘surgical stress’ as compared with transapical.
In the context of aortic stenosis, in which the treatment
is associated with immediate improvement of haemody-
namic, these factors may play a secondary role. But in the
case of FMR treatment, in which mitral regurgitation
treatment is associated with a transient increase in after-
load, minimization of invasiveness may be key for the
success of the procedures.
Technical open issues with transcatheter
mitral valve implantation and transcatheter
mitral valve repair
Proven that TMVI is feasible and that with improvement
of the technologies it would increase its applicability,
several open issues remain today regarding the perform-
ances of the device. One of the technical challenges
of TMVI is the fixation of the prosthesis in mitral pos-
ition. A fixation method relying solely on radial force is
questionable: in patients with both DMR and FMR
mitral annulus is usually dilated, so a very large device
is required to obtain adequate radial force to allow proper
fixation. However, the use of a large device may increase
the risk of damage to the stent of the device, which may
be fractured by the continuous movement of the LV in a
high-pressure environment. Additional fixation elements,
in addition to radial force, would be required to ensure
proper fixation of the device to LV or to the other
elements of the subvalvular apparatus. This is particu-
larly important if we consider that one of the target of
TMVI would be treat different causes with a single
device: not only DMR and FMR are different; DMR
include a wide spectrum of different pathological aspects,
ranging fromBarlow disease (in which the excess of tissue
determines an excess of movement that could prevent
optimal fixation) to fibroelastic deficiency with isolated
segmental prolapse (in which the lack of tissue may not
assure a landing zone for the device).
Adjunctive open issues to be considered regarding long-
term performance of TMVI devices are the risk of leaflets
damage and the risk of LVOT obstruction.
As repair technologies are concerned, several challenges
should be addressed. First, due to a wide variability
of potential lesions underlying mitral regurgitation, a
series of different technologies should be available,
and physicians dedicated to transcatheter mitral inter-
ventions should become expert in using more than one
device if they want to address most potential patients.
Currently, MitraClip has been a winning device also
because it is versatile, and it can be used both in patients
with FMR and DMR. However, MitraClip implantation
is a procedure very different from other interventions. In
addition to the transeptal puncture, the procedure is more
a robotic ‘surgical like’ endovascular procedure, with
free-floating navigation in a three-dimensional space.
In addition, differently from most interventional pro-
cedures, MitraClip requires advanced three-dimensional
echocardiographic guidance to achieve good results.
Learning curve of MitraClip is longer than for Transcath-
eter Aortic Valve Implantation and requires a skill set
that differs from that of a conventional interventional
cardiologist or a cardiac surgeon. The same limitations
and concerns apply to most repair technologies. From a
technical standpoint, most repair technologies on the
horizon require advanced and specific skills, which
may limit the fast expansion of TMVR, as compared
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with TVMI, in which reproducibility can be higher and
learning curve may be shorter.19
Some technologies for TMVR are easier to perform, such
as coronary sinus annuloplasty. However, as they are
based on unproven surgical ground, their efficacy in
the short and long term should be still demonstrated.
Other devices are expected to bemore effective, but their
implantation may be technically more demanding, with
a consequent lack of reproducibility.
Recently, direct annuloplasty is becoming available.
Direct mitral valve annuloplasty repair is a very promising
approach for TMVR, as it closely reproduces a gold-
standard surgical method. The Cardioband (ValtechCar-
dio Inc., Or Yehuda Israel) is the closest transcatheter
device to a surgical prosthetic ring.20 It is delivered from a
transeptal approach, and the implant is performed on the
atrial side of the mitral annulus. A surgical-like adjustable
Dacron band is implanted from trigone to trigone, by
means of multiple anchors. Ongoing feasibility trial is
enrolling high-risk patients with FMR. Initial clinical
data are promising, showing that Cardioband implan-
tation is associated with significant reduction of mitral
regurgitation, increased leaflet coaptation surface and
consistent septo-lateral annular dimension.21 Recently,
the device has been granted the CE mark, and it is
available for clinical use in Europe.
Promising initial clinical results have been showed also
with the Mitralign device (Mitralign Inc.,Tewksbury,
MA USA) that performs selective applications of the
mitral annulus by deploying couples of transannular
pledgets in the annulus. Patient enrolment in the CE
mark trial is completed, but the device is still not avail-
able for clinical use (Martinez-Clark P. MITRALIGN IN
FUNCTIONAL MITRAL REGURGITATION, Paris,
EuroPCR 2014).
The Accucinch System (Guided Delivery Systems, Santa
Clara, CAUSA) is another direct annuloplasty device that
uses the retrograde transventricular approach. A series of
anchors are implanted beneath the mitral valve in the
basilar LV. These anchors are connected by a nitinol wire
in which tethering the cord cinches the basal LV and
mitral annulus. The Accucinch System also causes remo-
delling of the basal portion of the LV and is unique in
this respect.
Today, the main concern about mitral direct annuloplasty
repair is that these procedures are technically very chal-
lenging, and this aspect could limit their rapid and
effective adoption in the real world.
TMVR armamentarium also includes artificial chordae
implantation, which are anchored to the LV apex to
restore mitral valve competency (NeoChord Inc., Eden
Prairie, Minnesota, USA). This procedure is performed
through a transapical, off-pump, beating heart approach.
It has been used successfully in several patients, with the
evidence of a learning curve. Long-term durability of this
approach remains an issue.
Different ventricular or atrial remodelling devices
complete the wide spectrum of TMVR technologies,
but limited clinical data are today available for these
approaches.22
Limitations of repair and replacement:
durability and need for anticoagulation
Durability of a tissue valve in mitral position is a major
concern in surgery, especially in younger patients. So far,
patients who undergo transcatheter mitral procedures are
mainly high-risk, elderly or inoperable patients. In this
context, durability of a transcatheter mitral prosthesis has
represented a minor issue.
However, if transcatheter procedures aim to become a
realistic alternative to surgery and expand indications to
a lower risk population, durability of the device should
be considered as a priority. The degeneration process of
a biological prosthesis starts in average 5 years after
operation in mitral position.9 Durability of biological
prosthesis in mitral position is largely suboptimal in
patients younger than 65 years,23 mainly due to the
high-pressure gradient between left atrium and LV.
Durability is a major issue also for mitral repair. Four-year
results of the EVEREST II trial24 showed that when
acute procedural result is optimal, transcatheter mitral
repair is durable. However, in case of mitral regurgitation
persistence or recurrence after mitral repair, outcomes are
poor, with reduced survival, increased risk of cardiac
events and reduced likelihood of reverse remodelling.25
Acute successful reduction of mitral regurgitation is
fundamental to provide durable results in TMVR,
suggesting that patients eligible for reparative procedures
should be treated only in high-volume high-experienced
centres, exactly as for reparative surgery.26
All the patients who undergo TMVI would probably
require long-term anticoagulation. Although at the
moment no long-term data are available, it is likely that
duration of anticoagulation will be lifelong. Chronic
anticoagulation is associated with increased risk of hae-
morrhagic and thrombotic events, suggesting that
patients with an artificial prosthetic valve in mitral pos-
ition, differently from patients receiving valve repair,
never have a restored expectancy of life compared with
the age-matched population.10 Risk of prosthetic valve
endocarditis is another issue. The patients treated with a
mitral prosthesis are not really cured: they will change
their bad-prognosis disease (mitral regurgitation) to
another disease with a much better prognosis, which
we could call ‘prosthetic valve disease’. This aspect
cannot be accepted if an expansion of the indications
towards a lower risk population is advocated.
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Towards a prognostic approach: safety rather
than efficacy is the key for a surgical-like
early indication with transcatheter mitral
procedures
Many physicians consider transcatheter mitral tech-
niques as the natural and inevitable evolution of modern
mitral surgery. However, if transcatheter procedures
aim to expand indications to a lower risk population,
interventional indications will inevitably move towards
a prognostic rather than palliative approach.
Current evidence suggests that when patients are treated
in a too advanced clinical status, outcomes become poor
and transcatheter mitral procedures are unable to modify
the clinical course of the disease and to influence the
prognosis.27 Surgical experience with mitral valve inter-
vention showed that early timing is crucial to achieve a
substantial prognostic benefit: restore expectancy of life
in DMR patients and obtain reverse remodelling in FMR
patients.7 It is a matter of fact that the impact of the
intervention will be much more efficient when executed
early in the clinical course of the disease. Several issues
raise concerns on the role of TMVI in patients in their
early stage of the disease. Only a very well tolerated
procedure can justify a transcatheter therapy as a first-line
option. If we consider safety and early indication, repair
should be preferred to TMVI due to the lack of the
consequences of a prosthesis (including anticoagulant
therapy, risk of structural valve deterioration and risk
of infection), which can’t be accepted if a prognostic and
early therapeutic approach is assumed.
When considering an early indication, the safety of a
procedure plays a much more important role than the
efficacy. A typical example is cardiac resynchronization
therapy (CRT): a widely accepted heart failure therapy,
even if clinical efficacy is achieved only in about 60–70%
of the cases.28 Patients are referred for CRT, even if there
is a 30–40% rate of nonresponders, because it is con-
ceived as a well tolerated therapy and patients are send to
get a chance of improvement, without much risk. There-
fore, safety is the key for early indication, and it will be in
the future the first indicator of success for a procedure.
The complementary role of repair and
replacement: the Mitral Toolbox
TMVI has the potential to be technically simpler and
more versatile as compared with repair; in addition,
TMVI will be more predictable in terms of mitral regur-
gitation reduction. Durability, safety and distortion of
the physiology remain major concerns. Repair is more
complex, and it is applicable only in selected patients,
with a less predictable mitral regurgitation reduction. On
the other hand, durability is very good in many patients,
if procedural success is achieved. Impact on physiology
is minimal, and safety profile is higher. Therefore,
TMVR may in the near future aspire to provide early
indication in lower risk patients, according to a surgical-
like prognostic approach.
TMVI will be complementary therapeutic option for a
great number of patients, especially in an advanced phase
of the disease, with both DMR and FMR, who are not
amenable for valve repair. Transcatheter mitral repair
should remain the first-line therapy whenever feasible
and will be mainly performed in highly experienced
centres. Careful patient selection will be extremely
important to define the complementary clinical role of
TMVI and TMVR.
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